Bace1as Role in Heart Failure (BACE1AS-HF)

NCT ID: NCT06213493

Last Updated: 2025-04-30

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 630 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-03-12
• Study Completion Date: 2024-11-30

Brief Summary

The objective of this project is 1) to explore the clinical relevance of BACE1-AS and BACE1 as therapeutic targets and 2) to evaluate their potentiality as biomarkers in ischemic heart failure (HF).

The first aim will be studied by validating in left ventricle biopsies in patients with post-ischemic heart failure the transcriptome and DNA methylation status data obtained in cell lines where the expression of BACE1-AS has been modulated.

The investigation of BACE1-AS and BACE1 as biomarkers will be obtained by using peripheral blood mononuclear cells (PBMCs) from patients with acute coronary syndrome (ACS) treated with percutaneous angioplasty (PCI) procedure and undergoing to left ventricular remodeling. Furthermore, PBMCs from patients with chronic ischemic HF recruited from the Istituti Clinici Scientifici Maugeri Pavia will be also used. From the data obtained from these patients and from non-decompensated subjects, the levels of BACE1-AS and BACE1 in the blood will be measured and correlated with each other and with β-amyloid levels (βA), as well as with clinically relevant parameters.

Detailed Description

1.1) Validation of transcriptomic data obtained in vitro: The transcriptome of the AC16 cardiomyocyte cell line in which the expression of BACE1-AS was induced by lentivirus vectors will be analyzed, thus identifying the transcripts specifically modulated by BACE1-AS. The data obtained in vitro will be validated by analyzing the RNAs extracted from 20 HF patients and 20 controls. These RNA samples are already available thanks to the RNA_HF_AS project "Study of the transcriptome in heart failure and aortic stenosis" (San Raffaele Hospital - Milan, Ethics Committee CE 85/int/2016).

1.2) Validation of epigenetic data: The effect of BACE1-AS on the state of DNA methylation will be studied in the AC16 cardiomyocyte cell line. In over-expressing BACE1-AS cells, DNA hypomethylation will be evaluated by MS-HRM and pyrosequencing studies of bisulfite-modified genomic DNA of 69 enhancer sequences identified by us as candidates in preliminary studies. The data thus obtained will be validated in 20 cardiac biopsies from patients with post-ischemic HF and in 20 controls. Left ventricular biopsies will be taken after obtaining informed consent from 20 patients suffering from non-terminal dilated cardiomyopathy (DCM) undergoing left ventricular reconstruction (SVR) surgery at the San Donato Policlinico. A sufficient number of samples with these characteristics have already been obtained from IRCCS Policlinico San Donato as part of the RNA_HF_AS project (San Raffaele Hospital - Milan, Ethics Committee CE 85/int/2016). and not completely used for the study.

1.3) Study of the expression levels of BACE1-AS, BACE1 in PBMC of patients with ischemic cardiomyopathy.

The expression levels of BACE1 and BACE1-AS will be measured in PBMCs from the following groups:

Group 1:

130 ACS patients with left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) < 45%) at 12 months follow-up after PCI, as well as 100 control subjects, recruited from the Interventional Cardiology Unit of the IRCCS Policlinico San Donato. The measurements of BACE1, BACE1-AS and βA will be carried out at the Molecular Cardiology Laboratory of the IRCCS Policlinico San Donato. These activities are included among those approved in the RNA_ACS protocol (Ethics Committee of the San Raffaele Hospital - Milan 14/int/2020) "RNA as prognostic biomarkers in patients with acute coronary syndrome"

Group 2:

240 patients with chronic post-ischemic HF and 120 age/sex-matched healthy controls. The recruitment of this group and measurements of BACE1, BACE1-AS and βA will be carried out at the Istituti Clinici Scientifici Maugeri Pavia.

Conditions

Heart Failure; Acute Coronary Syndrome

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

Non end-stage heart failure

Measurement of tissutal RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction

measurement of RNAs

Intervention Type: DIAGNOSTIC_TEST

RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

ACS patients

Measurement of circulating RNAs in acute coronary syndrome (ACS) patients treated with percutaneous angioplasty and undergoing to ventricle remodelling

measurement of RNAs

Intervention Type: DIAGNOSTIC_TEST

RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

HF patients

Measurement of circulating RNAs in heart failure patients

measurement of RNAs

Intervention Type: DIAGNOSTIC_TEST

RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

Controls

Measurement of RNAs in individuals not affected by cardiovascular diseases

measurement of RNAs

Intervention Type: DIAGNOSTIC_TEST

RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

Interventions

measurement of RNAs

RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• left ventricular reconstruction surgery (SVR)
• ESVI >35 ml/m2
• EF<40%
• previous anterior transmural infarction
• age 40-75 years

• Age >18 years
• Patients with ACS (first episode), defined according to the ESC 2017 guidelines [19]
• Informed consent to enrollment in the study

1. All patients admitted to Rehabilitation Cardiology at the Cardiology Department of ICS Maugeri with a diagnosis of chronic heart failure on an ischemic or "acute" basis due to exacerbation of chronic heart failure due to previous ischemia and whose therapies have been optimized at the moment of enlistment.

2. NYHA Class II-III at the time of enlistment;

3. Age over 18 years;

4. Informed consent signed at the time of enrollment in the study.

Exclusion Criteria

• ESVI <35 ml/m2
• EF>40%
• Tempo from E unknown
• Pregnant women
• Patients with genetic diseases
• Patients suffering from malignant neoplasm
• Subjects with collagenopathies
• Subjects undergoing chemo/radiotherapy
• Subjects undergoing prolonged steroid therapy
• Subjects with known active infectious diseases
• Subjects with positive serology for HIV, HBV (not vaccinated), HCV.

2. Patients with ACS and left ventricular dysfunction 12 months after percutaneous angioplasty

• Severe heart valve disease or other conditions requiring cardiac surgery
• Previous cardiac surgery including coronary artery bypass grafting
• Total chronic occlusions
• Patients with known hypersensitivity or contraindication to any of the following drugs:

heparin aspirin, clopidogrel, ticlopidine, sirolimus, everolimus.

• Any contraindication to implantation of drug-eluting stents (DES)
• Patients with previous documented myocardial infarction;
• LVEF <30% before PCI
• Patients in cardiogenic shock
• Patients with advanced STEMI (> 48 h from the onset of symptoms/Q waves on ECG) or undergoing fibrinolysis;
• Patients with known previous cardiomyopathy with LVEF < 40%
• Patients suffering from malignant neoplasms or systemic pathologies with a quoad vitam prognosis of less than 1 year;
• Patients suffering from known active infectious diseases;
• Patients who are unable to express valid informed consent at the time of enrollment
• Pregnant women

3. Patients with chronic post-ischemic HF ( recruitment at the Istituti Clinici Scientifici Maugeri Pavia)

1. Denial of informed consent;

2. End-stage renal disease;

3. Presence of ACS, stroke, transient ischemic attack, major cardiovascular surgery, percutaneous coronary angioplasty or carotid angioplasty in the previous 3 months;

4. Patients undergoing cardiac transplantation or on the active list for cardiac transplantation or undergoing LVAD implantation;

5. Presence of hemodynamically significant mitral or aortic valve disease except mitral insufficiency due to ventricular dilatation;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Istituti Clinici Scientifici Maugeri di Pavia

UNKNOWN

Sponsor Role: collaborator

IRCCS Policlinico S. Donato

OTHER

Sponsor Role: lead

Responsible Party

Fabio Martelli

Director of Molecular Cardiology Laboratory

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Fabio Martelli, PhD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Policlinico S. Donato

Locations

Irccs Policlinico San Donato

San Donato Milanese, Milan, Italy

Countries

Italy

Other Identifiers

BACE1AS_HF- RF-2019-12368521

Identifier Type: -

Identifier Source: org_study_id